Drug Interaction Report
3 potential interactions and/or warnings found for the following 2 drugs:
- Danziten (nilotinib)
- nafcillin
Interactions between your drugs
nafcillin nilotinib
Applies to: nafcillin, Danziten (nilotinib)
MONITOR: Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of nilotinib, which is primarily metabolized by the isoenzyme. In healthy subjects receiving the potent CYP450 3A4 inducer rifampin (600 mg once daily for 12 days), nilotinib systemic exposure (AUC) was reduced by approximately 80%. Data are not available for nilotinib in combination with other, less potent CYP450 3A4 inducers.
MANAGEMENT: Patients receiving nilotinib with CYP450 3A4 inducers should be monitored for potentially diminished pharmacologic response to nilotinib. Concomitant use should be avoided if an interaction is suspected.
References (1)
- (2007) "Product Information. Tasigna (nilotinib)." Novartis Pharmaceuticals
Drug and food interactions
nilotinib food
Applies to: Danziten (nilotinib)
GENERALLY AVOID: Grapefruit juice may increase the plasma concentrations of nilotinib. The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruits. Because nilotinib is associated with concentration-dependent prolongation of the QT interval, increased levels may potentiate the risk of ventricular arrhythmias such as torsade de pointes and sudden death.
ADJUST DOSING INTERVAL: Food increases the oral bioavailability of nilotinib. The mechanism of interaction is unknown. Compared to the fast state, nilotinib systemic exposure (AUC) increased by 82% when the dose was given 30 minutes after a high-fat meal. Because nilotinib is associated with concentration-dependent prolongation of the QT interval, increased levels may potentiate the risk of ventricular arrhythmias such as torsade de pointes and sudden death.
MANAGEMENT: Patients treated with nilotinib should avoid consumption of grapefruit, grapefruit juice, and any supplement containing grapefruit extract. In addition, no food should be consumed for at least 2 hours before and 1 hour after a nilotinib dose.
References (1)
- (2007) "Product Information. Tasigna (nilotinib)." Novartis Pharmaceuticals
nafcillin food
Applies to: nafcillin
ADJUST DOSING INTERVAL: Certain penicillins may exhibit reduced gastrointestinal absorption in the presence of food. The therapeutic effect of the antimicrobial may be reduced.
MANAGEMENT: The interacting penicillin should be administered one hour before or two hours after meals. Penicillin V and amoxicillin are not affected by food and may be given without regard to meals.
References (6)
- Neu HC (1974) "Antimicrobial activity and human pharmacology of amoxicillin." J Infect Dis, 129, s123-31
- Welling PG, Huang H, Koch PA, Madsen PO (1977) "Bioavailability of ampicillin and amoxicillin in fasted and nonfasted subjects." J Pharm Sci, 66, p. 549-52
- McCarthy CG, Finland M (1960) "Absorption and excretion of four penicillins." N Engl J Med, 263, p. 315-26
- Cronk GA, Wheatley WB, Fellers GF, Albright H (1960) "The relationship of food intake to the absorption of potassium alpha-phenoxyethyl penicillin and potassium phenoxymethyl penicillin from the gastrointestinal tract." Am J Med Sci, 240, p. 219-25
- Klein JO, Sabath LD, Finland M (1963) "Laboratory studies on oxacillin. I: in vitro activity against staphylococci and some other bacterial pathogens. II: absorption and urinary excretion in normal young." Am J Med Sci, 245, p. 399-411
- Neuvonen PJ, Elonen E, Pentikainen PJ (1977) "Comparative effect of food on absorption of ampicillin and pivampicillin." J Int Med Res, 5, p. 71-6
Therapeutic duplication warnings
No duplication warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
See also:
Hydrea
Hydrea is used for chronic myelogenous leukemia, head and neck cancer
Sprycel
Sprycel is used to treat chronic myeloid leukemia and acute lymphoblastic leukemia. Learn about ...
Taltz
Taltz (ixekizumab) is used to treat plaque psoriasis, psoriatic arthritis, and ankylosing ...
Gleevec
Gleevec is targeted cancer therapy for specific types of leukemia (blood cancer), bone marrow ...
Cytoxan
Cytoxan is used for acute lymphocytic leukemia, acute nonlymphocytic leukemia, breast cancer ...
Tasigna
Tasigna (nilotinib) is used to treat Philadelphia chromosome positive chronic myeloid leukemia ...
Scemblix
Scemblix (asciminib) is an oral kinase inhibitor that may be used to treat adults with a type of ...
Bosulif
Bosulif is a kinase inhibitor that may be used to treat adults and some children aged 1 year and ...
Iclusig
Iclusig (ponatinib) used to treat a type of blood cancer called chronic myeloid leukemia (CML), or ...
Learn more
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.